AlphAIAlphAI — Financial news for AI agents
tipranks.comSEP 141 min read$CEVA

Ceva upgraded to Buy at StoneX following recent selloff

StoneX upgraded Ceva to Buy from Hold, setting a $42 price target. The firm cited a 30% share price decline since mid-July and potential upside for FY27 and FY28. The analyst also noted possible revenue acceleration as a catalyst.

Original reporting
tipranks.com
Published Sep 14, 2026, 11:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 3:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Ceva upgraded to Buy at StoneX following recent selloff — source image
Source · tipranks.com
Decision brief

The 30-second read

$CEVABullishMed
01

Why it matters

The upgrade provides a fresh catalyst that could drive the stock toward the $42 target, offering a buying opportunity for traders.

02

Market read

The upgrade is a primary piece of company news that may influence Ceva's price action and sector sentiment.

03

What to watch

Potential regulatory risks and competition are not addressed in the upgrade.

Relevance 7/10Novelty 7/10Timing: today

Background

Ceva, a US-listed biotech, received an upgrade from StoneX after a 30% selloff since mid-July.

Company-level read

Ticker impact

$CEVABullishMedium confidence
Context

StoneX upgraded Ceva to Buy from Hold with a $42 price target, citing recent selloff and catalysts.

Expected impact

Share price may rise toward the $42 target.

Evidence & confidence

Upgrade is based on recent selloff, revenue acceleration expectations and FY27/FY28 upside scenario.

Market effects

Sector

Biotech sector may see modest uplift as analyst upgrades signal confidence in pipeline.

Regional

US biotech stocks could benefit from the positive sentiment.

Global

Limited to investors tracking US-listed biotech companies.

Counterpoint

What could challenge this read

The upgrade may be premature if upcoming trial data disappoints.

Key entities

  • Company
    Ceva

    US biotech firm (ticker CEVA).

  • Research Firm
    StoneX

    Analyst firm that issued the upgrade.

Read at source← All news

Related articles

OCT 27
$COHRMed

Coherent Soars 6%, Lumentum Up 8% as StoneX Starts Both With Buy, Sees 103% Upside

Coherent (COHR) and Lumentum (LITE) shares rose 6% and 8% respectively after StoneX initiated coverage with Buy ratings and price targets of $425 and $1,200. StoneX cites Coherent's six-inch InP laser production and Lumentum's market position in high-speed InP lasers and cloud transceivers. Coherent's earnings estimates have been rising, with fiscal 2027 EPS expected at $9.39. StoneX's target implies a 45x multiple on fiscal 2027 earnings, above Coherent's five-year average of 24x.

finance.yahoo.com2 min
OCT 27
$RMBSMed

Rambus stock price target maintained at $165 by StoneX on product momentum

StoneX maintained a Buy rating and $165 price target on Rambus (NASDAQ:RMBS) after its Q3 2026 results and Q4 guidance beat expectations. The company reported $0.84 EPS and $218.3M revenue, driven by strong product and silicon IP demand. Other analysts raised targets but kept Neutral ratings. Rambus shares are down 50% from their 52-week high, trading at 29x StoneX's earnings estimates.

investing.com2 min
OCT 27
High

Lumentum Stock Jumps 8% on StoneX $1,200 Target

Lumentum's stock rose 8.19% to $818.10 after StoneX initiated coverage with a Buy rating and a $1,200 price target. The company's products are used in AI and data-center infrastructure. Coherent and Applied Optoelectronics also gained. Lumentum's next earnings report is due on 5 November.

financefeeds.com2 min
OCT 26
$LITEHigh

Lumentum, Coherent Rise as StoneX Backs Optical Names

Lumentum LITE and Coherent COHR shares rose 7.99% and 5.16% respectively after StoneX initiated coverage with Buy ratings. StoneX set a $1,200 price target for Lumentum, above its 52-week high. MaxLinear MXL CEO highlighted strong demand for optical components, with estimates for pluggable units rising to 200 million by 2027-2028.

gurufocus.com2 min
OCT 26
$LITEHigh

Lumentum and Coherent Stocks Jump 3% as StoneX Unveils Bold Price Targets

Lumentum (LITE) and Coherent (COHR) shares rose 3% after StoneX initiated coverage with Buy ratings and price targets of $1,200 and $425, respectively. Analyst Cody Acree cited growing demand for optical tech in AI data centers and near-packaged optics deployment acceleration. Coherent plans to expand indium phosphide production and expects $3B quarterly revenue by late 2027.

finance.yahoo.com1 min